tradingkey.logo

Apogee Therapeutics Announces Positive Interim Results From Phase 1B Trial Of Apg808

ReutersMay 12, 2025 11:08 AM

- Apogee Therapeutics Inc APGE.O:

  • APOGEE THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS FROM THE PHASE 1B TRIAL OF APG808, ITS NOVEL HALF-LIFE EXTENDED IL-4RΑ ANTIBODY, IN PATIENTS WITH MILD-TO-MODERATE ASTHMA

  • APOGEE THERAPEUTICS INC: APG808 WAS WELL TOLERATED WITH A FAVORABLE SAFETY PROFILE CONSISTENT WITH ANTI-IL-4RΑ CLASS

  • APOGEE THERAPEUTICS: APG808 SHOWED POTENTIAL FOR DURABLE DISEASE CONTROL IN ASTHMA WITH SUSTAINED FENO DECREASE FROM BASELINE OF 50% AT 12 WEEKS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI